FDA clears Aurobindo’s Rizatriptan Benzoate orally disintegrating tablets

New Drug Approvals

India-based Aurobindo Pharma has obtained final FDA approvals to manufacture and market Rizatriptan Benzoate orally disintegrating tablets (ODT) 5mg and 10mg (ANDA 203062)…

read more at

http://drugdiscovery.pharmaceutical-business-review.com/news/fda-clears-aurobindos-rizatriptan-benzoate-orally-disintegrating-tablets-030713

 

Rizatriptan (trade name Maxalt) is a 5-HT1 agonist triptan drug developed by Merck & Co. for the treatment of migraine headaches. It is available in strengths of 5 and 10 mg as tablets and orally disintegrating tablets (Maxalt-MLT).

Maxalt obtained approval by the United States Food and Drug Administration (FDA) on June 29, 1998. It is a second-generation triptan.

Rizatriptan is available only by prescription in Australia, the United StatesCanada andNew Zealand. Similarly, it is classed as a POM (Prescription Only Medicine) in the United KingdomItaly (as Rizaliv), Israel (as Rizalt), The NetherlandsCroatia and Spain (asMaxalt)

View original post

Advertisements

About luciavazine

PHARMA PROFESSIONAL, ITALY
This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s